Trial Watch

Leading Results Leading Results

Challenged Results Challenged Results

Bristol-Myers Squibb Reports ELOQUENT-1 Trial Misses Primary Endpoint

Bristol-Myers Squibb Reports ELOQUENT-1 Trial Misses Primary Endpoint

Bristol-Myers Squibb announced topline results from ELOQUENT-1, a Phase 3 trial evaluating the combination of Empliciti (elotuzumab) plus Revlimid (lenalidomide) and dexamethasone (ERd), versus Revlimid and dexamethasone alone (Rd), in patients with newly diagnosed,...

subscribe

subscribe
University at Buffalo
subscribe

Pin It on Pinterest